[LOGO NEWS RELEASEystar Bio-Pharmaceutical Announces Revenue of $20.9 Million For Third Quarter Fiscal Year 2011 Revenues up 12.6%; Netome up 16.2%; EPS of $1.08 Per Basic and Fully Diluted Share XIAN, CHINA November 14, 2011 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2011 Highlights]
[LOGO NEWS RELEASEystar Bio-Pharmaceutical Announces Revenue of $20.9 Million For Third Quarter Fiscal Year 2011 Revenues up 12.6%; Netome up 16.2%; EPS of $1.08 Per Basic and Fully Diluted Share XIAN, CHINA November 14, 2011 -- -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), Third Quarter 2011 Highlights]
[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page No. 3 PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements 4 Condensed Consolidated Balance Sheets as of September 30, 2011 (unaudited) and December 31, 2010 F-1 Condensed Consolidated Statements of Income and Other Comprehensive Income for the Three and Nine Months Ended September 30, 2011 and 2010 (unaudited) F-2 Condensed Consolidated] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of SKYSTAR BIO-PHARMACEUTICAL COMPANY; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q of SKYSTAR BIO-PHARMACEUTICAL COMPANY; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer November 14, 2011] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Bing Mei Chief Financial Officer November 14, 2011]
[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page No. 3 PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements 4 Condensed Consolidated Balance Sheets as of September 30, 2011 (unaudited) and December 31, 2010 F-1 Condensed Consolidated Statements of Income and Other Comprehensive Income for the Three and Nine Months Ended September 30, 2011 and 2010 (unaudited) F-2 Condensed Consolidated] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of SKYSTAR BIO-PHARMACEUTICAL COMPANY; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q of SKYSTAR BIO-PHARMACEUTICAL COMPANY; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer November 14, 2011] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Bing Mei Chief Financial Officer November 14, 2011]
[FORM 10-Q (Mark One) x September 30, 2011 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]
[FORM 10-Q (Mark One) x September 30, 2011 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]
[SCHEDULE 14A INFORMATION þ o Check the appropriate box: o Preliminary Proxy Statement o þ Definitive Proxy Statement o Definitive Additional Materials o CHINA PHARMA HOLDINGS, INC Payment of Filing Fee (Check the appropriate box): þ No fee required.]
[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX PageNo. 3 PART I.FINANCIAL INFORMATION Item 1.ndensednsolidated Financial Statements 4ndensednsolidated Balance Sheets of September 30, 2011 (unaudited) and December 31, 2010 F-1ndensednsolidated Statements ofome and Othermprehensiveomefor the Three and Nine Months Ended September 30, 2011 and 2010 (unaudited)] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, WeibingLu, certify that: 1. I have reviewed this quarterly report on Form 10-Q ofYSTARBIO-PHARMACEUTICALCOMPANY; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q ofYSTARBIO-PHARMACEUTICALCOMPANY; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. WeibingLu Chief Executive Officer November 14, 2011 v240211_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Bing Mei Chief Financial Officer November 14, 2011]
[FORM 10-Q (Mark One) x For the quarterly period ended September 30, 2011 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number,] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer & Chairman, Chief Accounting Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director]
[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX PageNo. 3 PART I.FINANCIAL INFORMATION Item 1.ndensednsolidated Financial Statements 4ndensednsolidated Balance Sheets of September 30, 2011 (unaudited) and December 31, 2010 F-1ndensednsolidated Statements ofome and Othermprehensiveomefor the Three and Nine Months Ended September 30, 2011 and 2010 (unaudited)] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, WeibingLu, certify that: 1. I have reviewed this quarterly report on Form 10-Q ofYSTARBIO-PHARMACEUTICALCOMPANY; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q ofYSTARBIO-PHARMACEUTICALCOMPANY; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. WeibingLu Chief Executive Officer November 14, 2011 v240211_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Bing Mei Chief Financial Officer November 14, 2011]
